KBC Group
BPMC

KBC Group’s Blueprint Medicines BPMC Stock Holding History

KBC Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,776
Closed -$228K – 1731
2025
Q2 		$228K Sell
1,776
-947
-35% -$98.4K ﹤0.01% 820
2025
Q1 		$241K Buy
2,723
+98
+4% +$9.56K ﹤0.01% 967
2024
Q4 		$229K Buy
2,625
+1,023
+64% +$93.7K ﹤0.01% 1050
2024
Q3 		$148K Hold
1,602
– – ﹤0.01% 1059
2024
Q2 		$173K Buy
1,602
+281
+21% +$28.1K ﹤0.01% 917
2024
Q1 		$125K Hold
1,321
– – ﹤0.01% 1019
2023
Q4 		$122K Hold
1,321
– – ﹤0.01% 976
2023
Q3 		$66K Buy
+1,321
New +$70.6K ﹤0.01% 1228

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

KBC Group's BPMC Position: Q3 2025 in Review

KBC Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,776 shares — an estimated $228K sold.

KBC Group first reported a position in BPMC in Q3 2023 and held it in 8 quarters. The position peaked at $241K in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • KBC Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • KBC Group sold 1,776 Blueprint Medicines shares in Q3 2025, an estimated $228K.
  • KBC Group first reported a position in Blueprint Medicines in Q3 2023 and held it in 8 quarters.
  • KBC Group's Blueprint Medicines position peaked at $241K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on KBC Group's 13F filing for Q3 2025, filed 20 Jan 2026.